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Introduction
Crohn’s disease (CD) is an inflammatory disorder of the
gastrointestinal (GI) tract that is both chronic and relap-
sing. In addition to affecting the GI tract, CD has several
extra-intestinal manifestations. Arthritis is a common,
occurring in approximately 30% of CD patients. Here
we report a patient with CD who had treatment resis-
tant artrthritis.
Results
A 4 years old girl was admitted because of right hip pain.
When she was 1 year old was diagnosed with Crohn’s
disease and taken sulfasalazine and corticosteroid. She
had septic arthritis in her right hip one year ago. On
admission, we have found pain and limitation in right
hip. Also she was growth retardation. In her laboratory
findings, acute phase reactants were elevated (white
blood cells :20 500 /mm³, Thrombocyte : 596 000/ mm³,
ESH:120 mm/h, CRP 50,2 mg/L). She had also anemia
(Hemoglobine : 8 gr/dl). We found ANA and HLA B27
were negative. We detected arthritis in right hip joint and
bilateral sacroiliac joints in her MRI. Glucocorticoids and
methotrexate (MTX) was started effectively; however, the
patient did not reach complete remission. Therefore eta-
nercept was added her therapy. We found homozygote
MEFV mutation (M694V/M694V) and cholchine was
added in her therapy.
After one year, a severe arthritis flare occurred, with an
aggressive polyarticular course. In consideration of the
lack of control obtained through the etanercept adminis-
tration. We then decided to switch from etanercept to
infliximab), which was administered at 7 dose. Despite this
therapy, symptoms and laboratory findings did not regress.
We started canakinumab (2mg/kg/month) therapy. Her
arthritis was recovery on canacinumab in 3 months.
Conclusion
Interleukin-1 (IL-1) is a highly active pro-inflammatory
cytokine that lowers pain thresholds and damages tissues.
Monotherapy blocking IL-1 activity in autoinflammatory
syndromes results in a rapid and sustained reduction in
disease severity, including reversal of inflammation-
mediated loss of sight, hearing and organ function.
The pathogenesis of CD may be mediated by IL-1, and
canakinumab may be useful when this disorder is unre-
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